NCT03065335View on ClinicalTrials.gov

Neuropharmacologic Imaging and Biomarker Assessments of Response to Acute and Repeated-Dosed Ketamine Infusions in Major Depressive Disorder

PHASE1RecruitingINTERVENTIONAL
Enrollment

150

Participants

Timeline

Start Date

May 25, 2017

Primary Completion Date

January 1, 2026

Study Completion Date

January 1, 2028

Conditions
Healthy VolunteerMajor Depressive DisorderDepression
Interventions
DRUG

Ketamine

N-methyl-D-aspartate (NMDA) glutamate receptor (NMDA-R) antagonist

OTHER

Placebo

Placebo comparator

DEVICE

Cobot TS MV robotic arm for TMS

TMS-Cobot TS MV \[Axilum Robotics\] robotic arm for spatial positioning and orientation of the TMS coil

DEVICE

NeurOptics PLRTM-30000 Pupillometer

The Neu-rOptics PLRTM-3000 Pupillometer will use quantitative infrared technology to objectively and accurately measure pupil size and dynamics.

Trial Locations (1)

20892

RECRUITING

National Institutes of Health Clinical Center, Bethesda

All Listed Sponsors
lead

National Institute of Mental Health (NIMH)

NIH